KR101050565B1 - 모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법 - Google Patents

모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법 Download PDF

Info

Publication number
KR101050565B1
KR101050565B1 KR1020057011619A KR20057011619A KR101050565B1 KR 101050565 B1 KR101050565 B1 KR 101050565B1 KR 1020057011619 A KR1020057011619 A KR 1020057011619A KR 20057011619 A KR20057011619 A KR 20057011619A KR 101050565 B1 KR101050565 B1 KR 101050565B1
Authority
KR
South Korea
Prior art keywords
modafinil
enantiomer
enantiomers
temperature
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057011619A
Other languages
English (en)
Korean (ko)
Other versions
KR20050085847A (ko
Inventor
올리비어 네케브록
로랑 쿠르부아지에
스테파니 그라프
질 세후
제라드 코퀴에렐
세바스띠앙 로제
크리스틴 베쎄리에브르
프랑크 말렛
아드리안 잔 반 란게벨드
르프루스트 피에르
Original Assignee
세팔론 프랑스 (쏘시에떼 빠흐 악시옹 셍플리피에)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101050565(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세팔론 프랑스 (쏘시에떼 빠흐 악시옹 셍플리피에) filed Critical 세팔론 프랑스 (쏘시에떼 빠흐 악시옹 셍플리피에)
Publication of KR20050085847A publication Critical patent/KR20050085847A/ko
Application granted granted Critical
Publication of KR101050565B1 publication Critical patent/KR101050565B1/ko
Assigned to 테바 산테 reassignment 테바 산테 권리의 전부이전등록 Assignors: 세팔론 프랑스 (쏘시에떼 빠흐 악시옹 셍플리피에)
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057011619A 2002-12-20 2003-12-18 모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법 Expired - Lifetime KR101050565B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0216412 2002-12-20
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
PCT/FR2003/003799 WO2004060858A1 (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil

Publications (2)

Publication Number Publication Date
KR20050085847A KR20050085847A (ko) 2005-08-29
KR101050565B1 true KR101050565B1 (ko) 2011-07-19

Family

ID=32406320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057011619A Expired - Lifetime KR101050565B1 (ko) 2002-12-20 2003-12-18 모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법

Country Status (30)

Country Link
US (10) US7132570B2 (cg-RX-API-DMAC7.html)
EP (6) EP2676952A3 (cg-RX-API-DMAC7.html)
JP (2) JP4719471B2 (cg-RX-API-DMAC7.html)
KR (1) KR101050565B1 (cg-RX-API-DMAC7.html)
CN (5) CN100540533C (cg-RX-API-DMAC7.html)
AR (1) AR042546A1 (cg-RX-API-DMAC7.html)
AU (2) AU2003299349C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0316916B1 (cg-RX-API-DMAC7.html)
CA (2) CA2510096C (cg-RX-API-DMAC7.html)
CL (2) CL2007002450A1 (cg-RX-API-DMAC7.html)
CY (1) CY1114291T1 (cg-RX-API-DMAC7.html)
DK (1) DK2343275T3 (cg-RX-API-DMAC7.html)
EA (1) EA009592B1 (cg-RX-API-DMAC7.html)
EG (1) EG24849A (cg-RX-API-DMAC7.html)
ES (3) ES2575018T3 (cg-RX-API-DMAC7.html)
FR (1) FR2849029B1 (cg-RX-API-DMAC7.html)
HK (1) HK1225371A1 (cg-RX-API-DMAC7.html)
IL (1) IL169205A (cg-RX-API-DMAC7.html)
IS (1) IS7947A (cg-RX-API-DMAC7.html)
MX (1) MXPA05006525A (cg-RX-API-DMAC7.html)
MY (1) MY142926A (cg-RX-API-DMAC7.html)
NO (1) NO335724B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ540733A (cg-RX-API-DMAC7.html)
PL (1) PL377196A1 (cg-RX-API-DMAC7.html)
PT (1) PT2343275E (cg-RX-API-DMAC7.html)
SI (1) SI2343275T1 (cg-RX-API-DMAC7.html)
TW (1) TWI344952B (cg-RX-API-DMAC7.html)
UA (1) UA100964C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004060858A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504805B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077894A1 (en) * 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
IL163846A0 (en) 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7521553B2 (en) * 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
EP1986994A2 (en) * 2006-02-21 2008-11-05 Teva Pharmaceutical Industries Ltd Novel crystalline forms of armodafinil and preparation thereof
EP1954652A2 (en) 2006-03-01 2008-08-13 Teva Pharmaceutical Industries Ltd An improved process for the preparation of armodafinil
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
DK2056811T3 (en) * 2006-08-14 2018-05-22 Neurohealing Pharmaceuticals Inc Modafinil-based treatment for premature ejaculation
US20080214862A1 (en) * 2006-12-06 2008-09-04 Ben-Zion Dolitzky Processes for preparing armodafinil intermediate
CN101641090B (zh) * 2006-12-19 2012-12-05 亚勒斯有限公司 莫达非尼在制备治疗多动腿综合征的药物中的应用
CA2688430A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2009024863A2 (en) * 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
US7960586B2 (en) 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2292306B1 (en) 2009-09-02 2013-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
EP2501674A2 (en) * 2009-11-19 2012-09-26 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
EP2521546A4 (en) * 2010-01-07 2013-06-26 Vivus Inc TREATMENT OF THE OBSTRUCTIVE SLEEP APNEO SYNDROME COMBINED WITH ANTIBODY ANTIBODY AND AN ADDITIONAL ACTIVE SUBSTANCE
DK2649187T3 (da) 2010-12-08 2018-01-29 Codexis Inc Biokatalysatorer og fremgangsmåder til syntesen af armodafinil
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) * 2014-06-24 2019-11-05 Paypal, Inc. Surfacing related content based on user interaction with currently presented content
US10367985B2 (en) * 2014-07-23 2019-07-30 Orcam Technologies Ltd. Wearable apparatus and method for processing images including product descriptors
RU2674363C1 (ru) * 2014-11-27 2018-12-07 ДжиСи КОРПОРЕЙШН Средство для обработки поверхности восковой модели и способ изготовления зубного протеза
WO2017064723A1 (en) * 2015-10-12 2017-04-20 Natco Pharma Ltd An improved process for the preparation of armodafinil

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020043207A1 (en) * 2000-07-27 2002-04-18 Claude Singer Oxidation method for preparing highly pure modafinil, crystalline forms of modafinil, and methods of preparing the crystalline forms
US20040102523A1 (en) 2002-08-09 2004-05-27 Michel Broquaire Modafinil polymorphic forms

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en) 1968-02-13 1970-07-08 Inst Noguchi Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr) 1988-02-10 1990-07-27 Lafon Labor 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2671349B1 (fr) 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CN1249932A (zh) 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US20010036640A1 (en) 2000-04-25 2001-11-01 D'amico Kevin L. System and methods for the high throughput screening of polymorphs
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
DE10025756C2 (de) * 2000-05-25 2003-02-20 Cognis Deutschland Gmbh Lösungsvermittler
WO2005077894A1 (en) 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
US6835307B2 (en) * 2000-08-04 2004-12-28 Battelle Memorial Institute Thermal water treatment
US6919378B2 (en) 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CN1535139A (zh) 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
US7297346B2 (en) 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
WO2003014732A1 (en) 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
EP1466166B2 (en) 2002-01-15 2013-05-01 Avantium International B.V. Method for performing powder diffraction analysis
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CA2491908C (en) 2002-08-02 2011-09-13 Avantium International B.V. An assembly and method for performing parallel chemical experiments, in particular crystallisation experiments
CA2508165C (en) 2002-12-06 2014-05-06 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
KR101184797B1 (ko) 2003-09-04 2012-09-20 세파론, 인코포레이티드 모다피닐 조성물
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
BRPI0516001A (pt) 2004-10-13 2008-08-19 Pharmacia & Upjohn Co Llc formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
EP1986994A2 (en) * 2006-02-21 2008-11-05 Teva Pharmaceutical Industries Ltd Novel crystalline forms of armodafinil and preparation thereof
EP1954652A2 (en) 2006-03-01 2008-08-13 Teva Pharmaceutical Industries Ltd An improved process for the preparation of armodafinil
CA2688430A1 (en) 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2009024863A2 (en) 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
US7960586B2 (en) 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en) 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020043207A1 (en) * 2000-07-27 2002-04-18 Claude Singer Oxidation method for preparing highly pure modafinil, crystalline forms of modafinil, and methods of preparing the crystalline forms
US20040102523A1 (en) 2002-08-09 2004-05-27 Michel Broquaire Modafinil polymorphic forms
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms

Also Published As

Publication number Publication date
CN101012189A (zh) 2007-08-08
US20130274521A1 (en) 2013-10-17
US20090281192A1 (en) 2009-11-12
IS7947A (is) 2005-07-19
EA200501016A1 (ru) 2005-12-29
FR2849029A1 (fr) 2004-06-25
KR20050085847A (ko) 2005-08-29
CA2724305A1 (fr) 2004-07-22
EG24849A (en) 2010-10-27
CY1114291T1 (el) 2016-08-31
EP2679577A2 (fr) 2014-01-01
PT2343275E (pt) 2013-07-30
FR2849029B1 (fr) 2005-03-18
JP4719471B2 (ja) 2011-07-06
UA100964C2 (ru) 2013-02-25
PL377196A1 (pl) 2006-01-23
CA2510096A1 (fr) 2004-07-22
CN100540533C (zh) 2009-09-16
US20090281193A1 (en) 2009-11-12
CN106065007A (zh) 2016-11-02
DK2343275T3 (da) 2013-07-01
AR042546A1 (es) 2005-06-22
AU2003299349C1 (en) 2011-01-20
ES2627808T3 (es) 2017-07-31
EP2676952A2 (fr) 2013-12-25
TWI344952B (en) 2011-07-11
CN101914044A (zh) 2010-12-15
ZA200504805B (en) 2006-07-26
EP2679577A3 (fr) 2014-02-12
NO20052912D0 (no) 2005-06-15
EP2679576A2 (fr) 2014-01-01
BRPI0316916A8 (pt) 2015-09-22
NZ540733A (en) 2008-10-31
SI2343275T1 (sl) 2013-10-30
EP2679578B1 (fr) 2016-03-09
JP2006511588A (ja) 2006-04-06
ES2575018T3 (es) 2016-06-23
BR0316916A (pt) 2005-10-18
AU2010212462A1 (en) 2010-09-16
CA2510096C (fr) 2011-02-22
TW200419175A (en) 2004-10-01
HK1192222A1 (zh) 2014-08-15
JP5497680B2 (ja) 2014-05-21
EP1572635B1 (fr) 2017-04-12
US20060135621A1 (en) 2006-06-22
US9382200B2 (en) 2016-07-05
EA009592B1 (ru) 2008-02-28
NZ571235A (en) 2010-01-29
EP1572635A1 (fr) 2005-09-14
CN101012189B (zh) 2013-03-13
US20100048719A1 (en) 2010-02-25
ES2425023T3 (es) 2013-10-10
US7132570B2 (en) 2006-11-07
AU2003299349B2 (en) 2010-06-03
NO335724B1 (no) 2015-02-02
CN101654423A (zh) 2010-02-24
US20140031589A1 (en) 2014-01-30
WO2004060858A1 (fr) 2004-07-22
HK1225371A1 (zh) 2017-09-08
MXPA05006525A (es) 2005-12-05
US20100048718A1 (en) 2010-02-25
CL2016002640A1 (es) 2017-03-24
US20100048720A1 (en) 2010-02-25
US20100022653A1 (en) 2010-01-28
US20060241320A1 (en) 2006-10-26
EP2679578A2 (fr) 2014-01-01
JP2011102330A (ja) 2011-05-26
IL169205A (en) 2013-11-28
EP2343275B1 (fr) 2013-04-24
MY142926A (en) 2011-01-31
AU2003299349A8 (en) 2004-07-29
NO20052912L (no) 2005-07-19
AU2003299349A1 (en) 2004-07-29
US8975442B2 (en) 2015-03-10
BRPI0316916B1 (pt) 2021-11-30
CL2007002450A1 (es) 2009-01-16
EP2679576A3 (fr) 2014-02-12
EP2343275A3 (fr) 2011-08-17
EP2343275A2 (fr) 2011-07-13
US8729305B2 (en) 2014-05-20
EP2676952A3 (fr) 2014-02-12
EP2679578A3 (fr) 2014-03-19
CN1751021A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
KR20050085847A (ko) 모다피닐의 광학 거울상 이성질체들의 결정체 형태 및결정체 형태의 제조방법
HK1078309A (en) Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
HK1192221A (en) Preparation methods of crystalline forms of optical enantiomers of modafinil and pharmaceutical composition thereof
HK1192222B (en) Preparation method and crystalline form of optical enantiomers of modafinil
HK1192220A (en) Preparation methods of forms of optical enantiomers of modafinil and pharmaceutical composition thereof
HK1192218A (en) Preparation method and crystalline form iv of optical enantiomers of modafinil
HK1078309B (en) Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
HK1158171B (en) Crystalline form of the optical enantiomers of modafinil
HK1158171A1 (en) Crystalline form of the optical enantiomers of modafinil

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050620

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20070220

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081111

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100830

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110207

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100830

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110419

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110207

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110614

Appeal identifier: 2011101002956

Request date: 20110419

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110419

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110419

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20101101

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20081111

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080522

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20110614

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20110520

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110713

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110713

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140704

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140704

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150702

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150702

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160630

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180705

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180705

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200702

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20220630

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20240618

Termination category: Expiration of duration